The Alameda, California-based startup will use the funding to advance the commercialization of its rapid diagnostic platform for infectious diseases.
The firm's microfluidic-based technology collects and purifies genetic material, causing a complete PCR reaction that identifies diseases in liquid samples.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.
The firm will begin initial trials for antibiotic-resistant urinary tract infection detection in UK hospitals in early 2018.
The firm plans to expedite cell sorting for research labs with an inexpensive device that uses piezoelectric actuators and disposable microfluidics.
The SBIR grant will support the development of the firm's single-cell analysis platform, Tapestri.
The firm's microfluidic based technology collects and purifies genetic material, producing a complete PCR reaction to identify pathogens in liquid samples.
The firm will use the proceeds to develop its cell-sorting technology for cell line development, genomic sample preparation, CRISPR gene editing, and antibody discovery.
Hangzhou Chengyuan Genomics will provide single-cell analysis services and sell 1CellBio's InDrop instrument, reagents, and kits in China.
The system uses microfluidics and real-time image analysis to isolate single cells and provide visual documentation of monoclonality.
Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.
Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.
Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.
In Science this week: gut microbiome influences liver cancer growth, spread; and more.